Antibodies to cardiolipin may increase the risk of failure of peripheral vein bypasses  by Nielsen, T.G. et al.
Eur J Vasc Endovasc Surg 14, 177-184 (1997) 
Antibodies to Cardiolipin may Increase the Risk of Failure of 
Peripheral Vein Bypasses 
1". G. Nielsen tl, B. G. Nordestgaard 2, F. von Jessen 1, J. J. Andreasen 1, A. Wiik 3, N. H. H. Heegaard 3 and 
T. V. Schroeder  1 
~Department of Vascular Surgery, Rigshospitalet, University of Copenhagen, ZDepartment of Clinical Biochemistry, 
Herley University Hospital, University of Copenhagen and 3Department ofAutoimmunology, Statens Serum Institut, 
Copenhagen, Denmark 
Objectives: To assess the association between antibodies to cardiolipin and infrainguinal vein graft patency. 
Materials and Methods: Plasma levels of antibodies to cardiolipin, haemostatic fa tors, lipids and the smoking marker 
carboxyhaemoglobin were determined preoperatively and 6 weeks postoperatively in 80 patients undergoing infrainguinal 
vein bypass urgery. Bypass patency was assessed by ankle blood pressure measurements and ultrasound duplex scanning 
at 1 week, 6 weeks, 3, 6, 9 and 12 months. A localised increase in the graft peak systolic velocity by a factor of 2.5 or 
more was considered toindicate a significant stenosis. 
Results: Antibodies to cardiolipin were identified in seven (9%) patients preoperatively. In four of these seven patients 
the bypasses thrombosed within 3 months after surgery and another two developed stenoses. At 6 months the primary 
bypass patency, i.e. patency without stenosis, was 14% (95% confidence interval (CI) 0-33%) in patients with antibodies 
to cardiolipin, as opposed to 57% (95% C145-69%) in patients without hese antibodies (log rank test: p = 0.03). Diabetes 
mellitus was also associated with a reduced 6 months' primary bypass patency (38% (95% CI 16-60%) vs. 58% (95% 
CI 45-71%), p = 0.006). A Cox regression analysis howed that both the presence ofantibodies to cardiolipin and diabetes 
independently contributed towards predicting the overall risk of bypass failure. 
Conclusion: Antibodies to cardiolipin were identified in 9% of patients undergoing infrainguinal vein bypass urgery 
and appeared to be associated with increased risk of bypass failure. 
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Introduct ion 
Vein bypass is an established procedure in the man- 
agement of lower extremity ischaemia providing long- 
term patency rates ranging from 60-90%. 14 Bypass 
failures occurring within i month have mainly been at- 
tributed to technical factors related to the operation. 4'5 
The majority of late failures occurring more than 2 
years after surgery result from progressive athe- 
rosclerotic disease in the inflow artery, the graft, 
or the outflow artery. 4's Failures in the intermediate 
period between 1 month and 2 years after surgery 
constitute 70-80% of all failures and are mainly caused 
by graft or anastomotic stenoses. 4-9 Histopathological 
studies have shown that such peripheral vein bypass 
stenoses are characterised by intimal hyperplasia 
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predominantly composed of smooth muscle cells and 
varying degrees of fibrosis. 8'1°-12 Atherosclerotic 
changes are found only at a late stage. 8 The de- 
velopment of graft-related stenoses are assumed to be 
initiated by intraoperative in injury inducing platelet 
aggregation a d smooth muscle cell proliferation, lead- 
ing to intimal thickening and subsequently to luminal 
narrowing. 5'6'13 The presence of morphological changes 
in the saphenous vein prior to bypass grafting have 
been found to increase the risk of postoperative de- 
velopment of stenoses. 14'15 
Serological risk factors predict the outcome after 
coronary artery bypass surgery, 16'17 carotid end- 
arterectomy 18'19 or peripheral vascular inter- 
ventions. 2~22 The primary aim of this study was to 
assess prospectively the association between anti- 
bodies to cardiolipin and patency of infrainguinal vein 
bypasses when conventional risk factors were allowed 
for. A secondary aim was to assess lipoprotein (a) and 
antibodies to oxidised low density lipoprotein (LDL) 
as predictors of vein bypass patency. 
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Materials and Methods 
Subjects 
The study group comprised 103 patients scheduled 
for elective infrainguinal vein bypass urgery between 
July 1993 and May 1995. Another 190 patients who 
were operated on during the study period were not 
included for the following reasons: (i) anticoagulant 
treatment, (ii) vascular surgery or other interventional 
procedures within the last 3 months before surgery 
(which may all affect the levels of antibodies to car- 
diolipin), (iii) unwillingness to participate, (iv) emer- 
gency revascularisation (study personnel only present 
during daytime hours) or (v) participation in other 
research projects at our department (when more than 
one trial recruited patients, these were randomly as- 
signed to either trial, to reduce the risk of selection 
bias). The study group did not differ from the re- 
maining patients with respect to age, gender, smoking 
habits, diabetes, hypertension, indication for surgery 
or the level of the distal anastomosis. Twenty-three of 
the 103 patients were excluded at a later stage for the 
following reasons: seven were technically inoperable; 
in one patient dementia contraindicated surgery; eight 
patients in whom the saphenous vein was found to 
be inadequate had prosthetic grafts inserted (n = 7) or 
were referred to percutaneous transluminal an- 
gioplasty (n=l); and finally, preoperative blood 
samples were not available in seven patients. The 
median age of the remaining 53 men and 27 women 
was 70 (range 49-88). Ten (13%) patients had non- 
insulin dependent diabetes mellitus, and eight (10%) 
insulin-dependent diabetes mellitus. Previous aorto- 
iliac (n=12) or infrainguinal (n=19) arterial re- 
constructions had been performed in 25 (31%) patients. 
At the time of surgery, 48 (60%) patients were current 
smokers and 16 (20%) had quit smoking within the 
previous 10 years. The indication for surgery was 
disabling claudication in 14 patients (18%), rest pain 
in 33 patients (41%) and ischaemic ulceration or gan- 
grene in 33 patients (41%). Ulceration or gangrene 
occurred more often in patients with diabetes mellitus 
(78%) than in those without diabetes (31%) (p = 0.0009). 
The study was approved by the local Research Ethics 
Committee and informed consent was obtained in all 
cases. 
Surgery 
Preoperative evaluation included diagnostic ar- 
teriography and ultrasound duplex imaging of the 
greater saphenous vein using an Interspec RX400 
duplex scanner. Patent veins with an internal diameter 
of 2 mm or more were considered adequate. The level 
of the distal anastomosis was the above-knee popliteal 
artery in six patients (8%), the below-knee popliteal 
artery in 20 patients (25%) and a crural or pedal 
artery in 54 patients (68%). The bypass procedure 
was performed as described by Leather et aI. 1 For 
thrombosis prophylaxis, intravenous heparin (50 IU 
per kg body weight) was given during arterial clamp- 
ing. After surgery the patients received subcutaneous 
low molecular weight heparin (Logiparin 3500IU 
daily) until mobilisation and, unless contraindicated, 
acetylsalicylic acid 500 mga day thereafter. 
Bypass patency 
Bypass surveillance consisted of ankle blood pressure 
measurements and ultrasound uplex scanning of the 
graft at 1 week, 6 weeks, 3, 6, 9 and 12 months. The 
ultrasound examinations were performed with either 
a B&K Medical 3535 or an ATL Ultramark 9 HDI 
duplex scanner. A localised increase in the peak sys- 
tolic velocity of 250% or more in the graft was taken 
as indicating asignificant stenosis. Rdintervention was 
considered in patients with abnormal duplex findings 
in combination with a reduction in the ankle-brachial 
index (ABI) of more than 0.15. In one patient, who at 
the initial duplex examinations had normal findings 
but during follow-up moved to another part of the 
country, bypass patency was assessed by her general 
practitioner. 
Biochemical analysis 
Plasma concentration ofantibodies to cardiolipin, hae- 
mostatic factors, lipids and antibodies to oxidised LDL 
were measured 1-3 days prior to surgery and 6 weeks 
postoperatively. Measurements of these variables were 
only performed in the 80 patients included in the 
study and were assayed without knowledge of bypass 
patency. All preoperative blood samples were obtained 
after an overnight fast, but patients with diabetes were 
allowed breakfast prior to the postoperative sampling. 
Antibodies to cardiolipin were measured by an en- 
zyme-linked immunosorbent assay as described by 
Mouritzen et al. 23 and is based on the procedure pub- 
lished by Loizou et al. 24 Patients with IgM antibody 
levels of >30 arbitrary units or IgG antibody levels of 
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>35 arbitrary units were considered antibody positive. 
Using these threshold values the frequency of sero- 
logical positive tests in a normal control population is 
1%. 23 Plasma cholesterol, triglycerides, cholesterol in 
high density lipoprotein (HDL) and LDL were de- 
termined enzymatically (CHOD-PAP and GPO-PAP, 
Boehringer Mannheim, Mannheim, Germany). Lipo- 
protein (a) was measured turbidimetrically (DAKO 
A/S, Glostrup, Denmark). Antibodies to oxidised LDL 
were detected as described by Vaarala et al. 25 using 
LDL modified by treatment with malondialdehyde as 
given by Palinski et al. 26 Fibrinogen was analysed by the 
IL Test TM PT-fibrinogen (Instrumentation Laboratory, 
Milano, Italy) according to the instructions of the 
manufacturer. Tissue plasminogen activator (t-PA) was 
measured by solid-phase immunosorbent assay  27 and 
plasminogen activator inhibitor 1 (PAI-1) was meas- 
ured as previously described by Philips et al. 28 Con- 
tinued smoking after surgery was assessed by 
determination of carboxyhaemoglobin at 6 weeks 
using an OSM3 Hemoximeter® (Radiometer, Copen- 
hagen, Denmark) and a value of more than 2% was 
considered to indicate continued smoking. 
Statistics 
Continuous variables between the two groups were 
compared by the Mann-Whitney rank sum test. The 
Chi-squared test was used for comparison of cate- 
gorical data. Primary 6 months' bypass patency with- 
out stenosis was calculated by the life-table method. 
Comparison of patency rates in the two groups was 
performed for serological risk factors and patient char- 
acteristics by the log rank test. For continuous variables 
the 50th as well as the 75th percentiles were initially 
tested as threshold values, and the threshold yielding 
the lowest p value was used in the final patency 
analysis. A Cox proportional hazard regression model 
was used to assess independent associations: variables 
with p values of 0.1 or less in the individual analyses 
were entered into the model. A confidence limit of 
less than 0.05 was considered statistically significant. 
All analysis were performed with the Statistica soft- 
ware programme. 
Sample size calculation. Sample size was calculated as 
described by Altman. 29 It was assumed that antibodies 
to cardiolipin would be present in 20% of the patients 
and that the risk of bypass failure would be 70% in 
the antibody positive group as compared to 35% in 
the antibody negative group. On these assumptions 
102 patients would be required to show a difference 
in bypass failure rate between the groups, with an 80% 
power and a significance l vel of 5%. The frequency of 
antibodies to cardiolipin and the relative risk were 
adopted from a study on patients undergoing coronary 
artery bypass surgery, 17 as no major trial assessing 
antibodies to cardiolipin in patients with infrainguinal 
vein bypasses was available when the study was ini- 
tiated. 
Results 
Biochemical analysis 
Preoperatively, antibodies to cardiolipin were present 
in seven (9%) patients; six males and one female with 
a median age of 70 (range 50-81). In five cases the 
antibodies were of the IgM isotype and in two cases 
of the IgG isotype. At 6 weeks no new patients had 
developed antibodies to cardiolipin. 
Plasma levels of haemostatic factors, lipids and car- 
boxyhaemoglobin preoperatively and at 6 weeks are 
presented in Table 1. Values at 6 weeks postoperatively 
were not available for 18 patients who died or ex- 
perienced early occlusion of the bypass. When sero- 
logical risk factors were correlated with patient 
characteristics, it appeared that the preoperative fib- 
rinogen level was higher in patients with ulceration 
or gangrene compared with those operated for clau- 
dication or rest pain (20 vs. 15 micromol/1, p= 0.002). 
Table 1. Plasma levels of haemostatic factors, lipids and car- 
boxyhaemoglobin 1-3 days prior to surgery and 6 weeks post- 
operatively in patients undergoing peripheral vein bypass urgery. 
Preoperatively Six weeks after 
(n = 80) surgery (n = 62) 
Fibrinogen 15 (9-40) micromol/1 15 (7-32) micromol/1 
t-PA 29 (2-102) pmol/1 28 (3-63) pmoI/1 
PAI-1 183 (12-1708) pmol/1 198 (22-2642) prnol/1 
Triglycerides 1.9 (0.9-9.1) rnmol/1 1.6 (0.8-8.4) mmol/1 
Total cholesterol 6.1 (3.3-10.5) retool/1 6.2 (3.9-12.1) mmol/1 
LDL cholesterol 4.2 (1.8-8.0) retool/1 4.3 (1.9-9.1) mmol/1 
Antibodies to 6 (8%) 13 (21%) 
oxidised LDL 
HDL cholesterol 1.1 (0.4-2.1) mmol/1 1.2 (0.4-2.9) mmol/1 
Lipoproteh~ (a) 288 (1.4-1927) mg/dl 207 (1.6-2763) mg/dI 
Carboxyhaemoglobin N.A. 32 (52%) 
The carboxyhaemoglobin test was considered positive when above 
2%. Other variables are given as median values and ranges. 
N.A.=not available; t-PA=tissue ptasmhaogen activator; PAI-I= 
plasminogen activator inhibitor 1; LDL = low density lipoprotein; 
HDL =high density lipoprotein. 
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Perioperative vents 
Three patients died within 30 days of the operative 
procedure, resulting in a perioperative mortality of 
4%. Two patients died of cardiac causes and one of 
cancer of the stomach. Fifteen (19%) bypasses throm- 
bosed within 30 days. Though two were successfully 
reopened by surgical thrombectomy, they were coun- 
ted as early thromboses. 
Follow-up events 
The median follow-up period for the entire study 
group was 6 months (range 0-12 months). All patients 
with patent bypasses were followed for at least 6 
months. Among the 62 patients who stayed alive with 
patent bypasses at 30 days, graft-related stenoses were 
identified in 21 (34%): six stenoses were detected at 6 
weeks, seven at 3 months, four at 6 months, two at 9 
months and two at 12 months. Six surgical revisions of 
stenoses were performed in five patients. Ten bypasses 
thrombosed more than 30 days postoperatively. Five 
of these 10 late occlusions occurred in the group of 21 
patients with diagnosed graft stenoses. The overall 6 
months' primary bypass patency without stenosis was 
53% (95% CI 42-65%). 
Bypass patency according to risk factors 
Among the seven patients who preoperatively had 
antibodies to cardiolipin, bypass thromboses occurred 
in four and graft stenoses were identified in another 
two (Table 2). Three of the four thromboses occurred 
within I month and one was detected at 3 months. Of 
the five patients who preoperatively had IgM isotype 
antibodies to cardiolipin, bypass thrombosis occurred 
in four. The fifth patient developed a bypass stenosis 
at 3 months, which had regressed at 12 months. 
Using the log rank test for univariate valuation of 
individual risk factors, the presence of antibodies to 
cardiolipin and diabetes mellitus were both found to 
be correlated with graft patency without stenosis 
(Table 3). On a Cox regression analysis in which vari- 
ables with p values of 0.1 or less in the individual 
analysis were included, it was verified that diabetes 
mellitus and antibodies to cardiolipin each contributed 
independently in predicting the overall risk of bypass 
failure (Table 4). The 95% CI of the relative risk for 
Table 2. Antibody levels in arbitrary units and clinical outcome 
in seven patients with antibodies to cardiolipin before the bypass 
operation. 
Patient Preoperatively At 6 weeks 
IgM IgG IgM IgG 
Clinical outcome 
1 100 0 100 0 Thrombosis fir t 
day, patent at 12 
months following 
thrombectomy 
2 59 0 N.A.* N.A. Thrombosis first 
day, reocclusion 
after thrombectomy 
3 35 0 0 0 Thrombosis ninth 
day, thrombectomy 
not performed 
4 50 0 0 0 Stenosis at 3 
months, regressed 
at 12 months 
5 0 42 N.A. N .A .  Stenosis at 3 
months, persisted 
at 6 months 
6 88 0 73 0 Thrombosis at 3
months, 
thrombectomy not 
performed 
7 0 39 0 0 Patent without 
stenoses at12 
months 
Cut-off or IgM _< 30 arbitrary units, for IgG < 35 arbitrary units. 
* N.A. = not available. 
indication for surgery, fibrinogen and lipoprotein (a), 
however, all overlapped 1.0. 
Further stratification of patients according to time 
interval from surgery to the development of stenosis 
or thrombosis howed that no parameter predicted 
the risk of early (within 30 days after surgery) events. 
Among the 62 patients remaining at risk at 30 days, 
bypass patency free of stenosis was lower in patients 
with diabetes mellitus than in patients without (6 
months' primary bypass patency 57% (95% C129-85%) 
vs. 68% (95% CI 55-81%), p = 0.05) and a preoperative 
plasma fibrinogen concentration above the 75th per- 
centile was associated with reduced bypass patency 
(6 months' primary bypass patency free of stenosis 
58% (95% CI 32-84%) vs. 67% (95% CI 54-81%), p = 
0.05). 
Discussion 
Antibodies to cardiolipin as well as lupus anti- 
coagulant were first described in patients with sys- 
temic lupus erythematosus (SLE). In recent years 
antibodies to cardiolipin have, however, also been 
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Table 3. Primary 6 months' bypass patency without stenosis ac- 
cording to patients" characteristics and preoperative serological 
risk factors in 80 patients with infrainguinal vein bypasses. 
Characteristics Bypass patency p 
free of stenosis value 
(95% CI) 
Age _< 70 years (n = 43) 52% (37-67%) 0.48 
>70 years (n=37) 54% (38-71%) 
Gender Males (n=53) 59% (45-73%) 0.15 
Females (n=27) 42% (23-61%) 
Diabetes mellitus No (n = 62) 58% (45-71%) 0.006 
Yes (n = 18) 38% (16-60%) 
Current smokers No (n = 32) 56% (37-74%) 0.41 
Yes (n=48) 51% (37-66%) 
Indication for Claudication/rest pain 57% (43-72%) 0.10 
surgery (n = 47) 
Ulceration/gangrene 47% (28-65%) 
(n=33) 
Antibodies to Absent (n = 73) 57% (45-69%) 0.03 
cardiolipin (total) Present (n= 7) 14% (0-33%) 
Antibodies to Absent (n = 75) 57% (45-69%) 0.008 
cardiolipin (IgM) Present (n= 5) 0% (0-0%) 
Fibrinogen _<20 micromol/I (n=59) 55% (42-68%) 0.09 
>20 micromol/1 (n=17) 48% (24-71%) 
t-PA _<29 pmol/1 (n=39) 48% (32-65%) 0.45 
>29 pmol/1 (n=35) 59% (42-76%) 
PAI-1 _< 183 pmol/1 (n = 38) 56% (39-72%) 0.32 
>183 pmol/1 (n=37) 53% (36-69%) 
Triglycerides < 1.9 mmol/1 (n =40) 53% (37-69%) 0.44 
>1.9 mmol/1 (n=39) 52% (36-68%) 
Total cholesterol _<6.1 mmol/1 (n=41) 53% (37-69%) 0.41 
>6.1 mmol/1 (n=37) 54% (38-70%) 
LDL cholesterol _<4.2 mmoI/i (n=41) 47% (31-63%) 0.46 
>4.2 mmol/1 (n=37) 59% (43-75%) 
Antibodies to Absent (n = 74) 51% (39-63%) 0.18 
oxidised LDL Present (n = 6) 80% (49-100%) 
HDL cholesterol _<1.1 retool/1 (n=45) 56% (41-71% 0.46 
>1.1 mmoI/1 (n=33) 50% (33-68% 
Lipoprotein (a) _<288 mg/dl (n=40) 61% (45-76% 0.09 
>288 mg/dl (n =40) 46% (30-62% 
95% CI=95% confidence interval; t-PA=tissue plasminogen ac- 
tivator; PAI-1 = plasminogen activator inhibitor 1; LDL = low density 
lipoprotein; HDL =high density lipoprotein. 
Table 4. Cox regression analysis to find independent predictors 
of bypass failure. Variables with p values of 0.1 or less in univariate 
patency analyses (Table 3) were entered into the forced entry 
model. 95% CI = 95% confidence interval for the relative risk. 
Covariate Relative risk 95% CI 
Diabetes mellitus 2.89 1.29-6.48 
Indication for surgery 1.05 0.48-2.31 
Antibodies to cardiolipin 3.11 1.24-7.85 
Fibrinogen 0.87 0.34-2.21 
Lipoprotein (a) 1.42 0.76-2.65 
recognised in patients experiencing recurrent hrom- 
botic events but not fulfilling the criteria for SLE. 3°-32 
This condition is termed the pr imary antiphosphol ipid 
syndrome and is most frequently seen in younger 
females. 33 Manifestations of the pr imary anti- 
phosphol ipid syndrome include recurrent venous and 
arterial thrombosis, recurrent fetal loss, myocardial  
infarction, cerebrovascular events and bleeding com- 
plications. 3°-B4 The mechanism for this autoantibody- 
mediated thrombosis remains unclear. Interaction of 
antibodies to cardiolipin with phosphol ipid-binding 
plasma proteins such as f32-glycoprotein I, pro- 
thrombin, protein C and protein S is assumed to be 
involved in the process. 35 
A study by Ciocca et al. 36 identified the presence of 
antibodies to cardiolipin as a major risk factor in 
cardiovascular surgery. During a 6-year period 19 
patients with antibodies to cardiolipin underwent vari- 
ous cardiovascular surgical procedures. Sixteen (84%) 
anticardiolipin-positive patients suffered major post- 
operative complications related to either bleeding or 
thrombosis, and 12 (63%) died as a result of these 
complications. In a study on 83 patients undergoing 
coronary artery bypass grafting, Morton et al. 17 iden- 
tified antibodies to cardiolipin as a risk factor for late 
graft occlusion, and these investigators suggested graft 
failure to be an auto immune phenomenon. Likewise, 
Prieto et al. 37 found that antibodies to cardiolipin were 
associated with frequent hrombosis of haemodialysis 
fistulae. The present finding, that even low levels of 
antibodies to cardiolipin appeared to be associated 
with increased risk of infrainguinal bypass failure, has 
not previously been reported in a prospective follow- 
up study. Though the study was not based on a 
consecutive series of patients, we feel confident that the 
study group was representative of patients undergoing 
peripheral vein bypass surgery in our institution. 
Firstly, serological analyses were only performed in 
included patients, and therefore the antibody levels 
did not influence the recruitment, and secondly, patient 
characteristics were similar in the study group and 
the remaining patients operated on during the same 
period. Due to the rather small number  of antibody- 
positive patients in this series, larger studies, pre- 
ferably conducted as multicentre trials, are needed to 
confirm the role of antibodies to cardiolipin in the 
failure of infrainguinal vein bypasses. 
The published prevalence of antibodies to car- 
diolipin in patients with peripheral vascular disease 
ranges from 8% to 24%. This variation may, at least 
partly, be explained by differences in methodology, as 
a number  of tests for identification of antibodies to 
cardiolipin exist. Taylor et al. 3s found antibodies to 
cardiolipin in 55 of 234 patients admitted for peripheral 
vascular surgical procedures or amputation. Patients 
with antibodies to cardiolipin were 1.8 times more 
likely to have undergone previous lower extremity 
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reconstruction and 5.6 times more likely to have ex- 
perienced occlusion of a previous reconstruction. Fli- 
gelstone t aI. 39 assessed the incidence of antibodies to 
cardiolipin in 60 patients with peripheral aneurysmal 
or occlusive vascular disease and in 20 age-matched 
normal controls. Antibodies to cardiolipin were pres- 
ent in five (8%) patients as opposed to none in the 
control group. Similarly, antibodies were identified in 
seven (9%) patients preoperatively in this study. In 
the prospective study by Fligelstone t al. 39 and in this 
series, IgM was found to be the dominant isotype, but 
in the retrospective study by Taylor et al. s8 IgG was 
found more frequently. 
The approximately 10% prevalence of antibodies to 
cardiolipin in patients undergoing peripheral vascular 
reconstruction, leading potentially to increased peri- 
operative morbidity and mortality, suggests that in 
the future preoperative screening may be appropriate. 
However, before this is implemented further studies 
are needed to establish more firmly antibodies to 
cardiolipin as a risk factor for failure of infrainguinal 
vein bypasses. Treatment of the antiphospholipid syn- 
drome is even more controversial. Steroids, cytostatics 
or gammaglobulin may be used to control disease 
activity, 3.'34 but in patients with no history of throm- 
botic events or other autoimmune symptoms the in- 
dication for systemic anti-inflammatory agents eems 
questionable. In patients with a clearcut anti- 
phospholipid syndrome, closely controlled anti- 
coagulant therapy is effective in preventing recurrent 
thrombosis. 4° The use of anticoagulants in patients 
with antibodies to cardiolipin who undergo peripheral 
vascular reconstruction should be considered, 4. though 
documentation is currently lacking. 
In previous tudies a raised plasma fibrinogen level 
has been found to be associated with a reduced patency 
of peripheral vein bypasses. 2°'42 Though the influence of 
fibrinogen on overall bypass patency failed to achieve 
statistical significance in this study, the association 
between a raised fibrinogen concentration and an in- 
creased risk of late bypass failure supports the hypo- 
thesis of Hicks et al., 43 that fibrinogen is a risk factor 
for the development of graft stenoses. The finding of 
high fibrinogen levels in patients undergoing peri- 
pheral vascular surgery is in accord with previous 
observations. 39 The difference in plasma fibrinogen 
concentrations between patients with and without tis- 
sue loss presumably reflects the general increase of 
the acute phase proteins, which include fibrinogen, 
that occurs in response to critical ischaemia. 
Smoking has been identified as an important risk 
factor for failure of vascular econstructions in several 
publications. 19-21'42 The lack of association between car- 
boxyhaemoglobin at 6 weeks and bypass patency in 
this study may be related to the fact that a significant 
number of events occurred within 6 weeks. An im- 
mediate postoperative assay may be more valuable in 
studies with limited follow-up. 
Hyperlipidaemia is causally related to the de- 
velopment of atherosclerosis, 44-46 but the role of lipids 
in the development of restenosis following vascular 
intervention is unclear. In retrospective studies, 
patients with restenosis following carotid en- 
darterectomy were found to have higher levels of 
triglycerides and total cholesterol as compared to 
patients without evidence of restenosis. 18'47 However, 
a recent prospective study on 107 patients indicated 
that hyperlipidaemia is a risk factor for restenosis after 
carotid endarterectomy only in women. 19 In a study 
by Wiseman et al., 2~ plasma lipids did not adversely 
influence patency of 93 prosthetic femoropopliteal 
grafts. Studying 167 patients who had had coronary 
artery bypass surgery 0.7-14.3 years earlier, Hoff et 
al. 16 found that serum lipoprotein (a) was twice as high 
in 135 patients with angiographic restenoses as in 32 
patients without restenosis. Similarly, Cheshire et aI. 42 
found a higher lipoprotein (a) level in patients with 
bypass stenoses than in patients with no evidence of 
stenoses in a mixed group of vein grafts and prosthetic 
bypasses. These authors did not address the influence 
of lipoprotein (a) on bypass patency. Confirming the 
findings of Wiseman et aI., 2° a raised plasma con- 
centration of lipids was not a risk factor for bypass 
failure in this study. 
Oxidation of LDL is probably involved in athero- 
genesis 48 and antibodies to oxidised LDL have been 
identified in a high proportion of patients with ad- 
vanced atherosclerosis. 49 Our finding of a low in- 
cidence of antibodies to oxidised LDL in patients 
undergoing infrainguinal vein bypass surgery and 
the lack of association between these antibodies and 
bypass patency questions the role of LDL oxidation 
in the development of vein graft stenoses. 
In conclusion, antibodies to cardiolipin were iden- 
tified in 9% of patients undergoing infrainguinal vein 
bypass urgery and may be associated with increased 
risk of bypass failure. 
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